idiopathic membranous nephropathy
Conditions
Interventions
1:Pred 1mg/kg+MMF 0.5Q12h+FK506 2mg Q12h
2:Pred 1mg/kg+FK506 2mg Q12h
3:Pred 1mg/kg+CTX50mg BID
Sponsors
The first affiliated hospital of Zhengzhou University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Clinical pathology diagnosis of idiopathic membranous nephropathy; 2. Patients aged 18 to 65 years; 3. 24 hours urinary protein quantity at least 3.5g with eGFR more than 60ml/min/1.73m2; 4. Treatment with corticosteroids combined with an immunosuppressive agents (MMF, CTX, CNI) for 3 months without remission.
Exclusion criteria
Exclusion criteria: 1. Clinical pathology diagnosis of secondary membranous nephropathy; 2. Intravenous antibiotics should be used for severe infections within the 2 weeks before randomization; 3. Treatment with immunosuppressive agents, such as cyclosporine, Tripterygium Glycosides and so on, were more than one week within 1 month before enrollment; 4. Treatment with tacrolimus (except for topical use), MMF or cyclophosphamide within 1 month before enrollment; 5. Treatment with intravenous methylprednisolone pulse therapy within 1 month before enrollment; 6. Patients with a history of allergy to MMF, tacrolimus, cyclophosphamide or methylprednisolone; 7. eGFR is less than 60ml/min/1.73m2, or Scr more than 260umol/L (or 3mg/dL); 8. Patients with hepatic dysfun; 9. Patients with HBV or HCV Infection; Patients with active tuberculosis; Patients with severe immunodeficiency disease; 10. a history of gastrointestinal bleeding within 3 months before enrollment; 11. Patients with congenital heart diseases, arrhythmia, heart failure and other serious cardiovascular disease; 12. Patients with resistant hypertension; 13. Patients who are pregnant, nursing or unwilling to take contraceptive measures; 14. Recurrence of tumor patients within 5 years; 15. Patients who had participated in other clinical trials within 3 months before enrollment; 16. The condition of patients' is not suitable for this experiment by the research physician judgment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 24h-UP;Alb;Scr; | — |
Countries
China
Contacts
Public ContactZhangsuo Liu
Outcome results
None listed